对比增强超声LI-RADS非放疗治疗反应评估:应用、挑战与未来方向
该综述系统总结了ACR LI-RADS对比增强超声(CEUS)非放疗治疗反应评估(TRA)算法的词汇、标准及临床应用场景。CEUS TRA为消融、经动脉治疗或手术切除后的HCC提供实时、无辐射的评估替代方案,尤其在CT/MRI因禁忌或结果不确定时作为问题解决工具。文章还讨论了CEUS判读特有的陷阱及新兴应用方向。
要点
- CEUS TRA适用于HCC局部治疗后评估,尤其当CT/MRI不可评估或结果不确定时。
- 需注意CEUS特有陷阱:病灶显示不清、切除腔复杂、无法评估肝外病变。
- 新兴方向包括放疗后CEUS评估及Kupffer细胞特异性造影剂整合。
核心结论
- CEUS TRA算法为HCC非放疗局部治疗后提供实时、无辐射的评估选择,在传统影像不可评估时具有问题解决价值。
研究设计与样本
- 本文为综述,总结ACR LI-RADS CEUS非放疗治疗反应评估算法的词汇、标准及临床应用,未报告系统检索范围与纳入文献数量。
关键影像表现/征象
- CEUS可实时动态观察消融、经动脉治疗或手术切除后的治疗反应,但病灶显示不清、切除腔复杂及无法评估肝外病变是CEUS判读的特有陷阱。
诊断标准与关键数值
- ACR LI-RADS CEUS非放疗治疗反应评估(TRA)算法提供了针对消融、经动脉治疗或手术切除后HCC的评估标准,原文未列出具体敏感度、特异度、AUC或阈值数值。
临床应用与阅片要点
- 当CT/MRI因伪影、对比剂限制或治疗后异质性改变而不可评估时,可考虑CEUS TRA作为补充评估工具。
- 判读时需警惕CEUS对病灶显示不清、切除腔复杂及无法评估肝外病变的局限性。
局限性
- 原文指出CEUS存在病灶显示不清、切除腔复杂及无法评估肝外疾病的局限。
- 作为综述,本文未提供原始研究数据或定量汇总分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Hepatocellular carcinoma (HCC) requires nuanced treatment response assessment to balance oncologic control with preservation of liver function. CT and MRI, cornerstones of response evaluation, are often limited by contraindications to their use or indeterminate findings. The recently introduced ACR LI-RADS Contrast-Enhanced Ultrasound (CEUS) Non-Radiation Treatment Response Assessment (TRA) algorithm offers a real-time, radiation-free alternative for evaluating treated HCC after ablation, transarterial therapies, or surgical resection. This review summarizes the CEUS TRA lexicon, criteria, and application across common clinical scenarios, emphasizing its value as a troubleshooting tool when conventional imaging is non-evaluable due to artifacts, contrast limitations, or heterogeneous post-treatment changes. We highlight pitfalls unique to CEUS interpretation, including poor lesion visibility, resection cavity complexity, and the inability to assess extrahepatic disease. Emerging areas include CEUS assessment after radiation-based therapies and the potential for integration of Kupffer-cell-specific contrast agents. Together, these developments position CEUS as an increasingly important modality for precise, timely, and individualized management of HCC following non-radiation locoregional therapy.
引用
- Fetzer DT, Kono Y, Piscaglia F, et al. Contrast-enhanced ultrasound LI-RADS nonradiation treatment response assessment: applications, challenges, and future directions. Abdom Radiol (NY). 2026. PMID: 41961317. doi:10.1007/s00261-026-05469-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。